Editorial introductions : Current Opinion in Pediatrics

Secondary Logo

Journal Logo

Editorial introductions

Editorial introductions

Current Opinion in Pediatrics 22(6):p vii-ix, December 2010. | DOI: 10.1097/MOP.0b013e3283412601
  • Free

Current Opinion in Pediatrics was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of pediatrics is divided into 18 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who ident ifies the most important topics at that time. In addition to this, Hank Bernstein also invites a prominent authority in the field of Office Pediatrics to write on the subject for each issue. Here we are pleased to introduce the Section Editors for this issue.

Section Editors

Nathaniel H. Robin

FU1-1
Figure 1

Dr Robin grew up in Hempstead, New York, and attended Bowdoin College in Brunswick, Maine, USA. After graduating in 1985 as Phi Beta Kappa and Summa Cum Laude, Dr Robin attended Albert Einstein College of Medicine in the Bronx, New York, where he remained as a resident in pediatrics through 1992. He then proceeded to the Children's Hospital Philadelphia/University of Pennsylvania as a fellow in the Divisions of Human Genetics and Molecular Biology and Biochemical Genetics. Following his fellowship, he accepted a faculty position in the Department of Genetics at Case Western Reserve University School of Medicine in 1995. In 2003, Dr Robin joined the newly created Department of Genetics at the University of Alabama at Birmingham. Dr Robin is board certified both by the American Academy of Pediatrics and the American Board of Medical Genetics. His clinical practice is primarily as a general geneticist, with expertise in pediatric genetics, syndrome identification and genetic counseling. His areas of focused interest include craniofacial disorders, and the genetics of deafness. While maintaining an active clinical practice, Dr Robin has authored one book: Medical Genetics: Its Application to Speech, Hearing, and Craniofacial Disorders, 14 book chapters, over a dozen invited editorials and over 90 peer-review publications. His writings cover a wide range of topics in genetics and include descriptions and studies on a variety of genetic syndromes. He has published studies that have looked at genetics testing for deafness, and on ethical issues in genetic testing, including issues of confidentiality and duty to warn at risk relatives. Dr Robin is the residency program director at The University of Alabama at Birmingham, and is currently a member of the ACGME's National Residency Review Committee for Genetics.

Scott L. Pomeroy

FU2-1
Figure 2

Scott L. Pomeroy, Chair of the Department of Neurology, Neurologist-in-Chief of Children's Hospital Boston, USA and Bronson Crothers Professor of Neurology at Harvard Medical School, graduated from Miami University in Oxford, Ohio (summa cum laude, Phi Beta Kappa) and was the first graduate of the MD, PhD program at the University of Cincinnati (Alpha Omega Alpha, Bogan Research Award, PICO award). From 1982 to 1987, he trained in pediatrics at Children's Hospital Boston and in child neurology at Washington University in St. Louis. n 1989, he won the Child Neurology Society Young Investigator Award for work done as a postdoctoral fellow with Dale Purves at Washington University. He returned to Children's Hospital Boston in 1991, serving as Neurology Inpatient Service Chief (1994–8), Chair of the Neurology Residency Training Committee (1993–7), Director of the Mental Retardation Research Center Imaging Core (1995-present), and a member of the Neurology Executive Committee (1992-present). In 1991, he established the Neuro-Oncology Program within the Neurology Department and in 1992 co-founded the Children's Hospital/Dana-Farber Pediatric Brain Tumor Clinic. Dr Pomeroy was appointed Chairman of the Department of Neurology and Neurologist-in-Chief of Children's Hospital Boston in 2005.

Dr Pomeroy has been active in the Child Neurology Society, serving on the Awards Committee (1989–1993), as Chair of the Research Committee (1993–1997), and as a member of the Strategic Planning Committee (1997-present). He is Chair and Co-Chair respectively of the Tumor Biology Subcommittees of the Pediatric Brain Tumor Consortium and the Children's Oncology Group. In 1999, he co-directed a Neurobiology of Disease course on brain tumor biology for the Society for Neuroscience. Over the past three years, he has reviewed grants for the National Institutes of Health, Medical Research Council of Canada, the Alberta Cancer Foundation, National Cancer Institute of Canada, the Israel Science Foundation and the March of Dimes, was a session Co-Chair of the NCI/NINDS Brain Tumor Progress Review Group (2000), and served as a Consultant to the FDA Oncologic Drugs Committee (2001). He has been Chair of the Medical Advisory Board of the Brain Tumor Society since 1998. In 1999, Dr Pomeroy became the first recipient of the Kenneth B Schwartz Center Compassionate Caregiver Award. In 2000, he received the Boston Globe/Celtics “Heroes Among Us” Award and received citations from the Massachusetts Senate and House of Representatives.

Robert C. Tasker

FU3-1
Figure 3

Robert C. Tasker is Senior Lecturer in Paediatrics at the University of Cambridge School of Clinical Medicine, UK. He has been a consultant in the UK National Health Service for 17 years; first at Great Ormond Street Hospital for Children, London, and for the last 11 years at Addenbrooke's Hospital, Cambridge. He is an expert in the field of paediatric neurocritical care with expertise in clinical physiology and translational research interests in hypoxia-ischemia, trauma-induced white matter injury and neuroendocrinology. Over the last five years he has chaired the UK Paediatric Intensive Care Society Clinical Studies Group; the UK Medicines for Children Research Network Studies Group for Anaesthesia, Pain, Intensive Care and Cardiology; and the external advisory committee for the UK Centre for Maternal and Child Enquires project into morbidity and mortality from traumatic brain injury in childhood.

Mark P. Gorman

FU4-1
Figure 4

Mark P. Gorman is an Instructor in Neurology at Harvard Medical School and a staff pediatric neurologist at Children's Hospital Boston and Massachusetts General Hospital for Children, USA. After pediatric neurology residency at Children's Hospital Boston, Dr Gorman completed a fellowship in pediatric multiple sclerosis and related disorders sponsored by the Central New England Chapter of the National Multiple Sclerosis Society. Since 2008, he has directed the Pediatric Neuroimmunology Program in the Department of Neurology at Children's Hospital Boston and is the pediatric neurologist at the Partners Pediatric Multiple Sclerosis Center at the Massachusetts General Hospital for Children.

Luigi D. Notarangelo

FU5-1
Figure 5

Dr Notarangelo was born in Foggia and grew up in Rome. Italy. He attended Medical School at the University of Pavia and graduated Summa Cum Laude in 1980. He completed residencies in Pediatrics (1984), Allergy (1987) and Human Cytogenetics (1993). He accepted a faculty position as Assistant Professor in the Department of Pediatrics at the University of Brescia in 1986. From 1987 to 1989 he worked as a guest researcher at the Metabolism Branch, National Cancer Institute, NIH, in Bethesda, Maryland, USA. He was promoted to Associate Professor at the University of Brescia, Italy, in 1990, and to Full Professor of Pediatrics in 1996. From 2000 to 2006, Dr Notarangelo served as Chair of Department of Pediatrics at the University Hospital in Brescia. He was elected President of the European Society for Immune Deficiency from 2002 to 2006. Dr Notarangelo co-chairs the International Union of Immunological Societies Committee on Primary Immunodeficiencies. In 2006, he was recruited at Children's Hospital Boston, USA, where he is Jeffrey Modell Chair of Pediatric Immunology research, Professor of Pediatrics and Pathology at the Harvard Medical School, and scientist at the Manton Center for Orphan Disease Research. Dr Notarangelo's research interests focus on the molecular and cellular characterization of human primary immunodeficiencies, and development of novel therapeutic approaches for these disorders. He has discovered genetic defects leading to X-linked and autosomal recessive forms of hyper-IgM syndrome and Severe Combined Immune Deficiency (SCID) due to JAK3 deficiency. Dr Notarangelo has also unraveled the molecular bases of Omenn syndrome and of Xlinked thrombocytopenia. DrNotarangelo has participated at gene therapy trials for adenosine deaminase deficiency and is currently site Principal Investigator in a gene therapy trial for X-linked SCID. He has authored more than 350 peer-reviewed manuscripts and several book chapters.

Michael Cabana

FU6-1
Figure 6

Michael Cabana, MD, MPH, Professor of Pediatrics, Epidemiology and Biostatistics, is the Director of the Division of General Pediatrics at the University of California, San Francisco (UCSF), USA. He is a member of the core faculty at the Philip Lee Institute for Health Policy Studies at UCSF and Director of the General Pediatrics Fellowship Program at UCSF.

Dr Cabana's research interests include understanding variation in physician practice as it relates to quality of care, particularly in asthma. His work has focused on measurement of quality of care, physician use of clinical practice guidelines and primary prevention of asthma.

Dr Cabana completed his undergraduate medical training through the combined program at the University of Pennsylvania School of Medicine and the Wharton School of Business, where he earned a Masters Degree in Public Policy and Management. Dr Cabana trained in pediatrics at the Harriet Lane Service at the Johns Hopkins Children's Center. He continued at Johns Hopkins as a Robert Wood Johnson Clinical Scholar, where he completed his Masters in Public Health at the same institution.

Dr Cabana is currently the principal investigator for the Enhancing Pediatric Asthma Management Study (R-01 HL70771), a five-year study focused at improving physician management of pediatric asthma. He is also the principal investigator for the Trial of Infant Probiotic Supplementation (R-01 HL80074), a five-year randomized controlled trial to evaluate the effectiveness of probiotic supplementation in the prevention of early markers of asthma.

© 2010 Lippincott Williams & Wilkins, Inc.